GlassScriptPhysician profile
Niccole L Mcdaniel
NPI 1972834190
$5,107.93
in general payments reported to CMS, 2019-2025
44 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,793 · 2022: $1,486 · 2023: $960 · 2024: $600 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,019.97 | 2021-2024 | |
| Glaxosmithkline, LLC. | $514.64 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $385.96 | 2021-2023 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $379.24 | 2021-2024 | Relistor, Xifaxan |
| Amgen INC. | $328.01 | 2021-2024 | Repatha, Otezla |
| Abbott Laboratories | $188.86 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $182.24 | 2021-2024 | Mounjaro |
| Exact Sciences Corporation | $175.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $175.71 | 2021-2024 | Verquvo |
| Mylan Specialty L.P. | $165.40 | 2021-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $160.46 | 2021-2025 | Airsupra, Breztri, Lokelma |
| Indivior INC. | $158.28 | 2021-2025 | Sublocade |
| Sanofi-Aventis U.S. LLC | $141.95 | 2021-2022 | |
| Amarin Pharma, INC. | $140.64 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $110.40 | 2022-2024 | Rexulti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niccole Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.